Get started
Author

Xin Sun

Observed names: X Sun, X. Sun, X.C. Sun, Xin SUN, Xingxing Sun, xingxing Sun
Observed institutions: Hubei University of Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Sheng Jing Hospital, Peking Union Medical College Hospital, Jiangxi Science and Technology Normal University, National Cancer Center, Taihe Hospital, Peking University People's Hospital, National Clinical Research, Cancer Hospital of Chinese Academy of Medical Sciences, Jiangsu Province Hospital, Liaoning Cancer Hospital & Institute, First Affiliated Hospital Zhejiang University, Zhejiang University, Nanjing Medical University, China Medical University
ORCID: 0000-0003-0336-4769
Observed ORCIDs: 0000-0003-0336-4769, 0009-0002-6003-1565
OpenAlex ID: A5101432437
Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy
2021 · Zhouguang Hui, Yu Men, et al. · JAMA Oncology · 233
PDF
The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation
2020 · Jie He, Zhihui Zhou, et al. · European Journal of Medicinal Chemistry · 74
Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs
2017 · Yang Liu, Li SUN, et al. · OncoTargets and Therapy · 54
PDF
A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer
2019 · Li Ma, Yu Men, et al. · Radiology and Oncology · 51
PDF
Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy?
2017 · Jie-Tao Ma, Li Sun, et al. · Radiation Oncology · 44
PDF
Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients
2018 · Jingjing Kang, Joe Y. Chang, et al. · Journal of Cancer · 40
PDF
Anlotinib Enhances the Antitumor Activity of High‐Dose Irradiation Combined with Anti‐PD‐L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer
2022 · Meng Yuan, Yirui Zhai, et al. · Oxidative Medicine and Cellular Longevity · 35
PDF
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present)
2020 · Xin Sun, Shan Xu, et al. · Expert Opinion on Therapeutic Patents · 30
High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis
2020 · Xin Sun, Lei Wang, et al. · Frontiers in Oncology · 29
PDF
Design, synthesis and pharmacological evaluation of 2-arylurea-1,3,5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy
2022 · Xin Sun, Binliang Zhang, et al. · Bioorganic Chemistry · 21
XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer
2022 · Shan Xu, Xin Sun, et al. · Biomedicine & Pharmacotherapy · 21
Risk of cardiac‐related mortality in stage IIIA‐N2 non‐small cell lung cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database
2021 · Xin Sun, Yu Men, et al. · Thoracic Cancer · 16
PDF
Postoperative radiotherapy improves survival of patients with ypN2 non‐small cell lung cancer after neoadjuvant chemotherapy followed by surgery – A propensity score matching study of the Surveillance, Epidemiology, and End Results database
2021 · Yongxing Bao, Xu Yang, et al. · Thoracic Cancer · 14
Systemic Inflammation-Immune Status Predicts Survival in Stage III-N2 Non-Small Cell Lung Cancer
2019 · Jianyang Wang, Zhouguang Hui, et al. · The Annals of Thoracic Surgery · 14
PDF
Famitinib enhances the antitumor effect of radioimmunotherapy in murine lung cancer
2022 · Meng Yuan, Yirui Zhai, et al. · Thoracic Cancer · 13
PDF
Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma
2022 · Xin Sun, Jie Xu, et al. · International Journal of General Medicine · 11
PDF
Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma
2019 · Yang Liu, Zhi-Cheng Xiong, et al. · Translational Cancer Research · 10
PDF
Benefits of postoperative thoracic radiotherapy for small cell lung cancer subdivided by lymph node stage: a systematic review and meta-analysis
2017 · Shuling Zhang, Xin Sun, et al. · Journal of Thoracic Disease · 8
PDF
Optimizing fractionation schedules for de-escalation radiotherapy in head and neck cancers using deep reinforcement learning
2025 · Yongheng Yan, Xin Sun, et al. · Radiotherapy and Oncology · 7
PDF
Additional Radiotherapy With or Without Chemotherapy Following Endoscopic Resection for Stage I Esophageal Carcinoma: A Pilot Study
2021 · Xu Yang, Yu Men, et al. · Technology in Cancer Research & Treatment · 7
Combined neat model for the prognosis of postoperative stage III‐N2 non‐small cell lung cancer
2020 · Yirui Zhai, Zhouguang Hui, et al. · Thoracic Cancer · 5
A comparison between raltitrexed plus cisplatin and docetaxel plus cisplatin in concurrent chemoradiation for non-surgical esophageal squamous cell carcinoma
2021 · X. Xia, Z. Liu, et al. · Cancer/Radiothérapie · 2
A Cross-Sectional Study of Clinical Trials on Radiotherapy Combined with Immunotherapy
2019 · Z. Hui, M. Yuan, et al. · International Journal of Radiation Oncology*Biology*Physics · 2
PDF
99mTc-MIBI and 99mTc-MDP scintimammography for detecting breast carcinoma.
2000 · S Chen, W Liu, et al. · PubMed · 2
Adjuvant Radiotherapy is Safe and Effective for Patients with T1b-SM2 Esophageal Carcinoma After Endoscopic Resection – A Second Analysis From a Pilot Study
2021 · X. Yang, Y. Men, et al. · International Journal of Radiation Oncology*Biology*Physics · 1
PDF
Works count: 46
Citation count: 746
H-index: 14
I10-index: 17
Year
Topic
Type